LPA and coronary artery disorder: Currently, a phase 3 double-blind, randomized, placebo-controlled trial assessing the impact of olpasiran on the risk for CHD death, myocardial infarction, or urgent coronary revascularization in patients with ASCVD and elevated Lp(a) levels (≥200 nmol/L) is ongoing (Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a))—Outcomes Trial; NCT05581303).